NCT02387125.

Trial name or title	A phase Ib study evaluating the safety, tolerability and immunogenicity of CMB305 (sequentially administered LV305 and G305) in patients with locally advanced, relapsed, or metastatic cancer expressing NY‐ESO‐1
Methods	Non‐randomised open‐label multi‐centre phase Ib
Participants	69 participants with melanoma, sarcoma, ovarian cancer, or non‐small cell lung cancer that expresses NY‐ESO‐1
Interventions	CMB305 (sequentially administered LV305 (a dendritic cell‐targeting viral vector expressing the NY‐ESO‐1 gene) and G305 (NY‐ESO‐1 recombinant protein plus GLA‐SE))
Outcomes	Adverse events Clinical response Survival Immune response
Starting date	March 2015
Contact information
Notes	Recruiting, January 2018